No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ACCD Accolade
- 6.180
- -0.270-4.19%
Close Jun 14 16:00 ET
- 6.300
- +0.120+1.94%
Post 19:08 ET
484.25MMarket Cap-4646P/E (TTM)
6.390High6.180Low409.97KVolume6.390Open6.450Pre Close2.56MTurnover0.58%Turnover RatioLossP/E (Static)78.36MShares15.36052wk High1.09P/B435.96MFloat Cap6.18052wk Low--Dividend TTM70.54MShs Float65.250Historical High--Div YieldTTM3.26%Amplitude4.610Historical Low6.242Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Can Accolade (ACCD) Sustain an Annual Revenue Growth Rate of 20%?
Accolade to Announce Fiscal First Quarter 2025 Financial Results
PDF Version SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal first quarter 2025 financial results on Thursday, June 27, 2024, a
Is Accolade (NASDAQ:ACCD) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems
Observe.AI Launches Next-Gen Conversation Intelligence, Creating a Definitive Path to Value Realization For Generative AI in Contact Centers
New GenAI enhancements to Real-Time AI and Post-Interaction AI help contact center leaders rapidly drive value with effortless configurability and fast implementationSAN FRANCISCO--(BUSINESS WIRE)--Ob
Accolade To Present at William Blair Growth Stock Conference
PDF Version SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the William Blair Growth Stock Conference in Chicago on Tuesday,
Truist Financial Maintains Accolade(ACCD.US) With Buy Rating
Truist Financial analyst Jailendra Singh maintains $Accolade(ACCD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 33.0% and a total average return of -15.2% over t
Comments
Accolade's balance sheet seems manageable with its US$741.6m market cap, but needs monitoring. Its future profitability will impact its financial strength. However, its EBIT loss, negative free cash outflow of US$37m, and a US$123m accounting loss make it somewhat risky.
Health Check: How Prudently Does Accolade (NASDAQ:ACCD) Use Debt? 1
Investors seem to be banking on Accolade's strong future outlook, despite its slow growth in revenue. The high P/S ratio and share price suggest confidence in the company's future revenues.
Gainers:
• $Cytokinetics(CYTK.US$ +8.7% (prices offering of of $450.0 mln of 3.50% convertible senior notes due 2027)
• $XPeng(XPEV.US$ +3.4% (June deliveries)
• $NIO Inc(NIO.US$ +2.9% (June deliveries)
• $Bitfarms(BITF.US$ +2.7% (provides June 2022 production and mining operations update)
• $Accolade(ACCD.US$ +2.7% (In reaction to earnings/guidance)
• $BioCryst Pharmaceuticals(BCRX.US$ +2.6% (presents new data demonstrating...
• $Cytokinetics(CYTK.US$ +8.7% (prices offering of of $450.0 mln of 3.50% convertible senior notes due 2027)
• $XPeng(XPEV.US$ +3.4% (June deliveries)
• $NIO Inc(NIO.US$ +2.9% (June deliveries)
• $Bitfarms(BITF.US$ +2.7% (provides June 2022 production and mining operations update)
• $Accolade(ACCD.US$ +2.7% (In reaction to earnings/guidance)
• $BioCryst Pharmaceuticals(BCRX.US$ +2.6% (presents new data demonstrating...
18
1
Upgrades
• $Accolade(ACCD.US$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $6 (from $9)
• $Comerica(CMA.US$ : Piper Sandler Upgrades to Overweight from Neutral - PT $94 (from $90)
• $New Oriental(EDU.US$ : JPMorgan Upgrades to Neutral from Underweight - PT $14 (from $35)
• $EPAM Systems(EPAM.US$ : Piper Sandler Upgrades to Overweight from Neutral - PT $348 (from $359)
• $Empire State Realty Trust Inc(ESRT.US$ : Evercore ISI Upgrades to Outp...
• $Accolade(ACCD.US$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $6 (from $9)
• $Comerica(CMA.US$ : Piper Sandler Upgrades to Overweight from Neutral - PT $94 (from $90)
• $New Oriental(EDU.US$ : JPMorgan Upgrades to Neutral from Underweight - PT $14 (from $35)
• $EPAM Systems(EPAM.US$ : Piper Sandler Upgrades to Overweight from Neutral - PT $348 (from $359)
• $Empire State Realty Trust Inc(ESRT.US$ : Evercore ISI Upgrades to Outp...
18
1
thank youGainers:
• $GTY Technology(GTYH.US$ +118.1% (entered into a definitive agreement to be acquired by GI Partners )
• $Finch Therapeutics(FNCH.US$ +68.33% (announces removal of FDA clinical hold on CP101 IND)
• $Zymeworks(ZYME.US$ +42.34% (confirms receipt of non-binding proposal from All Blue Falcons for $10.50 per share in cash)
• $Hub Group(HUBG.US$ +16.3% (earnings reports)
• $Lantheus(LNTH.US$ +14.2% (earnings reports)
• $Mohawk Industries(MHK.US$ +13.7% (e...
• $GTY Technology(GTYH.US$ +118.1% (entered into a definitive agreement to be acquired by GI Partners )
• $Finch Therapeutics(FNCH.US$ +68.33% (announces removal of FDA clinical hold on CP101 IND)
• $Zymeworks(ZYME.US$ +42.34% (confirms receipt of non-binding proposal from All Blue Falcons for $10.50 per share in cash)
• $Hub Group(HUBG.US$ +16.3% (earnings reports)
• $Lantheus(LNTH.US$ +14.2% (earnings reports)
• $Mohawk Industries(MHK.US$ +13.7% (e...
18
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg